Blue Owl Capital Holdings LP
13F Reported Value
ⓘ$372.2M
Holdings
75
Latest Filing
2026-03-31
Filing Quarter
Q1 2026
Portfolio Overview
Blue Owl Capital Holdings LP disclosed 75 positions worth $372.2M in its Form 13F-HR for Q1 2026, led by $AKTS (Aktis Oncology, Inc.) at 15.2% of the equity portfolio, followed by $LRMR and $ENGN. During the quarter the fund opened 14 new positions and exited 23 — including a new stake in $AKTS and a full exit from $BLK. The portfolio is most concentrated in Healthcare (73.7% of disclosed assets). All figures are sourced directly from Blue Owl Capital Holdings LP’s Form 13F-HR filing with the SEC under CIK 1858703.
AI Fund Analysis
DiversifyingSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q1 2026
Click any card to unlockTop Holdings
- —
Quality
$56.6M3,161,348 sh - —
Quality
$32.0M7,120,007 sh - —
Quality
$30.1M4,416,353 sh - $27.3M2,143,626 sh
- —
Quality
$27.1M1,909,764 sh - —
Quality
$22.6M2,045,070 sh - —
Quality
$20.5M1,005,929 sh - —
Quality
$15.6M2,941,525 sh - —
Quality
$13.3M5,089,015 sh - 44.7
Quality
$13.0M4,236,888 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 Aktis Oncology, Inc.$AKTS | — | $56.6M | 3,161,348 |
 Larimar Therapeutics, Inc.$LRMR | — | $32.0M | 7,120,007 |
 enGene Therapeutics Inc.$ENGN | — | $30.1M | 4,416,353 |
 Nuveen Churchill Direct Lending Corp.$NCDL | — | $27.3M | 2,143,626 |
 Cullinan Therapeutics, Inc.$CGEM | — | $27.1M | 1,909,764 |
 Blue Owl Capital Corp$OBDC | — | $22.6M | 2,045,070 |
 MapLight Therapeutics, Inc.$MPLT | — | $20.5M | 1,005,929 |
 Compass Therapeutics, Inc.$CMPX | — | $15.6M | 2,941,525 |
 Context Therapeutics Inc.$CNTX | — | $13.3M | 5,089,015 |
 Holley Inc.$HLLY | 44.7 | $13.0M | 4,236,888 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Blue Owl Capital Holdings LP's 75 positions.
Showing top 10 of 75 holdings.
Sector Allocation
Healthcare
$274.3M
Other
$51.4M
Industrials
$19.5M
Technology
$14.4M
Consumer Discretionary
$6.1M
Real Estate
$2.7M
Financials
$1.6M
Energy
$1.3M
Full Holdings — Blue Owl Capital Holdings LP (Q1 2026)
All 75 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $AKTS | Aktis Oncology, Inc. | $56.6M | 15.2% | NEW | — |
| 2 | $LRMR | Larimar Therapeutics, Inc. | $32.0M | 8.6% | -48% | — |
| 3 | $ENGN | enGene Therapeutics Inc. | $30.1M | 8.1% | -34% | — |
| 4 | $NCDL | Nuveen Churchill Direct Lending Corp. | $27.3M | 7.3% | -50% | — |
| 5 | $CGEM | Cullinan Therapeutics, Inc. | $27.1M | 7.3% | -59% | — |
| 6 | $OBDC | Blue Owl Capital Corp | $22.6M | 6.1% | -50% | — |
| 7 | $MPLT | MapLight Therapeutics, Inc. | $20.5M | 5.5% | +54% | — |
| 8 | $CMPX | Compass Therapeutics, Inc. | $15.6M | 4.2% | -58% | — |
| 9 | $CNTX | Context Therapeutics Inc. | $13.3M | 3.6% | -66% | — |
| 10 | $HLLY | Holley Inc. | $13.0M | 3.5% | -49% | 44.7 |
| 11 |  $EYPT | EyePoint, Inc. | $11.8M | 3.2% | +16% | 10.3 |
| 12 |  $CRVS | Corvus Pharmaceuticals, Inc. | $8.0M | 2.1% | NEW | — |
| 13 |  $CNDT | CONDUENT Inc | $6.4M | 1.7% | -48% | 30 |
| 14 |  $RARE | Ultragenyx Pharmaceutical Inc. | $6.3M | 1.7% | -29% | 31 |
| 15 |  $AQST | Aquestive Therapeutics, Inc. | $5.6M | 1.5% | +28% | 11.7 |
| 16 |  $RYTM | RHYTHM PHARMACEUTICALS, INC. | $5.3M | 1.4% | NEW | 30.3 |
| 17 |  $CMPS | COMPASS Pathways plc | $5.1M | 1.4% | +92% | — |
| 18 |  $IMMX | Immix Biopharma, Inc. | $5.0M | 1.3% | -72% | — |
| 19 |  $IMA | ImageneBio, Inc. | $4.8M | 1.3% | -42% | 3.9 |
| 20 |  $CVEO | Civeo Corp | $4.8M | 1.3% | -76% | 27.9 |
| 21 |  $LENZ | LENZ Therapeutics, Inc. | $4.6M | 1.3% | +69% | 19.6 |
| 22 |  $ELDN | Eledon Pharmaceuticals, Inc. | $4.4M | 1.2% | -63% | — |
| 23 |  $KALV | KalVista Pharmaceuticals, Inc. | $4.3M | 1.2% | -70% | 25.9 |
| 24 |  $OVID | Ovid Therapeutics Inc. | $4.2M | 1.1% | NEW | 13.1 |
| 25 |  $PVLA | PALVELLA THERAPEUTICS, INC. | $3.9M | 1.1% | -61% | — |
| 26 |  $PLRX | PLIANT THERAPEUTICS, INC. | $3.7M | 1.0% | -50% | — |
| 27 |  $STWD | STARWOOD PROPERTY TRUST, INC. | $2.7M | 0.7% | NEW | 54.6 |
| 28 |  $ADCT | ADC Therapeutics SA | $2.6M | 0.7% | -50% | 16.3 |
| 29 |  $EVMN | Evommune, Inc. | $2.3M | 0.6% | NEW | — |
| 30 |  $DELL | Dell Technologies Inc. | $2.3M | 0.6% | -87% | 76 |
| 31 | $LRMR | Larimar Therapeutics, Inc. | $1.9M | 0.5% | NEW | — |
| 32 |  $ORIC | Oric Pharmaceuticals, Inc. | $1.9M | 0.5% | -85% | — |
| 33 |  $SGMT | Sagimet Biosciences Inc. | $1.7M | 0.5% | -87% | — |
| 34 |  $WW | WW INTERNATIONAL, INC. | $1.3M | 0.3% | NEW | 26.4 |
| 35 | $ENGN | enGene Therapeutics Inc. | $1.3M | 0.3% | +608% | — |
| 36 |  $EPD | ENTERPRISE PRODUCTS PARTNERS L.P. | $1.2M | 0.3% | -50% | 66.4 |
| 37 |  $FLD | Fold Holdings, Inc. | $1.1M | 0.3% | -50% | 7.5 |
| 38 | — | SYNTEC OPTICS HLDGS INC | $867,383 | 0.2% | -50% | — |
| 39 |  $MRKR | Marker Therapeutics, Inc. | $720,525 | 0.2% | -50% | — |
| 40 |  $MLYS | Mineralys Therapeutics, Inc. | $590,000 | 0.2% | +52% | — |
| 41 |  $NB | NIOCORP DEVELOPMENTS LTD | $524,964 | 0.1% | -82% | — |
| 42 | $CMPX | Compass Therapeutics, Inc. | $500,000 | 0.1% | NEW | — |
| 43 | — | BRAND ENGAGEMENT NETWORK INC | $416,702 | 0.1% | -69% | — |
| 44 |  $CAH | CARDINAL HEALTH INC | $363,031 | 0.1% | -50% | 58.6 |
| 45 |  $RZLV | REZOLVE AI PLC | $202,204 | 0.1% | -59% | — |
| 46 |  $PIPR | PIPER SANDLER COMPANIES | $185,863 | 0.1% | +100% | 64.4 |
| 47 |  $AMOD | ALPHA MODUS HOLDINGS, INC. | $145,809 | 0.0% | -50% | — |
| 48 |  $ET | Energy Transfer LP | $102,792 | 0.0% | NEW | 64.5 |
| 49 |  $DAIC | CID Holdco, Inc. | $94,751 | 0.0% | -50% | — |
| 50 |  $CAI | Caris Life Sciences, Inc. | $84,233 | 0.0% | NEW | 32 |
| 51 | — | VODAFONE GROUP PLC | $80,672 | 0.0% | NEW | — |
| 52 | — | ALPHA MODUS HLDGS INC | $74,187 | 0.0% | -50% | — |
| 53 |  $VKTX | Viking Therapeutics, Inc. | $68,000 | 0.0% | NEW | — |
| 54 |  $SHFS | SHF Holdings, Inc. | $62,995 | 0.0% | -50% | — |
| 55 |  $GOCO | GoHealth, Inc. | $61,563 | 0.0% | NEW | 17.7 |
| 56 |  $AEON | AEON Biopharma, Inc. | $41,506 | 0.0% | -51% | — |
| 57 |  $BGL | Blue Gold Ltd | $35,000 | 0.0% | -50% | — |
| 58 | — | SOUTHLAND HLDGS INC | $34,412 | 0.0% | -50% | — |
| 59 |  $RDZN | Roadzen Inc. | $31,500 | 0.0% | -50% | 26.4 |
| 60 |  $GPCR | Structure Therapeutics Inc. | $25,000 | 0.0% | NEW | — |
| 61 |  $BKSY | BlackSky Technology Inc. | $14,000 | 0.0% | -50% | 15.7 |
| 62 |  $OLMA | Olema Pharmaceuticals, Inc. | $10,000 | 0.0% | NEW | — |
| 63 |  $BDMD | Baird Medical Investment Holdings Ltd | $9,000 | 0.0% | -50% | — |
| 64 | $DAIC | CID Holdco, Inc. | $8,890 | 0.0% | -26% | — |
| 65 |  $DAVE | Dave Inc./DE | $7,763 | 0.0% | -50% | 78.1 |
| 66 | — | TEVOGEN BIO HLDGS INC | $6,000 | 0.0% | -50% | — |
| 67 |  $KPLT | Katapult Holdings, Inc. | $5,736 | 0.0% | NEW | 40.5 |
| 68 | — | STARDUST PWR INC | $2,667 | 0.0% | -74% | — |
| 69 |  $LIMN | Liminatus Pharma, Inc. | $2,000 | 0.0% | -50% | — |
| 70 |  $PGY | Pagaya Technologies Ltd. | $1,946 | 0.0% | -50% | — |
| 71 | — | XBP GLOBAL HOLDINGS INC | $1,487 | 0.0% | -50% | — |
| 72 |  $WALD | Waldencast plc | $1,333 | 0.0% | -50% | — |
| 73 |  $ASBP | Aspire Biopharma Holdings, Inc. | $1,000 | 0.0% | -50% | — |
| 74 |  $BTM | Bitcoin Depot Inc. | $1,000 | 0.0% | -50% | 46.7 |
| 75 | $KPLT | Katapult Holdings, Inc. | $0 | 0.0% | -50% | 40.5 |
New Positions (14)
$AKTS Aktis Oncology, Inc.$56.6M$CRVS Corvus Pharmaceuticals, Inc.$8.0M$RYTM RHYTHM PHARMACEUTICALS, INC.$5.3M$OVID Ovid Therapeutics Inc.$4.2M$STWD STARWOOD PROPERTY TRUST, INC.$2.7M$EVMN Evommune, Inc.$2.3M$WW WW INTERNATIONAL, INC.$1.3M$ET Energy Transfer LP$102,792$CAI Caris Life Sciences, Inc.$84,233$VKTX Viking Therapeutics, Inc.$68,000$GOCO GoHealth, Inc.$61,563$GPCR Structure Therapeutics Inc.$25,000$OLMA Olema Pharmaceuticals, Inc.$10,000Exited Positions (23)
$BLK BlackRock, Inc.
$PCOR PROCORE TECHNOLOGIES, INC.
$ROIV Roivant Sciences Ltd.
$IMRX Immuneering Corp
$PAYO Payoneer Global Inc.
$CNTA Centessa Pharmaceuticals plc
$NU Nu Holdings Ltd.
$JANX Janux Therapeutics, Inc.
$CHYM Chime Financial, Inc.
$DRTS Alpha Tau Medical Ltd.
$OMDA Omada Health, Inc.
$TTAN ServiceTitan, Inc.
$ANGX Angel Studios, Inc.
$LVWR LiveWire Group, Inc.Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Blue Owl Capital Holdings LP including:
Track Blue Owl Capital Holdings LP's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Blue Owl Capital Holdings LP and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Blue Owl Capital Holdings LP
13F Pro is an AI hedge fund tracker and stock research platform. For Blue Owl Capital Holdings LP (SEC CIK: 1858703), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Blue Owl Capital Holdings LP's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.